Introducing Signatera, a personalized, tumor-informed test

The Signatera ApproachПодробнее

SIGNATERA: PERSONALIZED BLOOD TEST DETECTS CANCER RECURRENCEПодробнее

Signatera for immunotherapy response monitoringПодробнее

Farshid Dayyani, MD | What is Signatera?Подробнее

Signatera - A New Blood Test to Detect CancerПодробнее

Advances in testing: A personalized, ctDNA assay for MRD detection and surveillanceПодробнее

Angela's Story with SignateraПодробнее

Introducing Signatera, a personalized, tumor-informed testПодробнее

About Signatera and ctDNAПодробнее

Axel Grothey, MD | What is Signatera?Подробнее

Signatera™ — Knowing Early Can Make a DifferenceПодробнее

Understand ctDNA TestingПодробнее

Signatera para el control de la respuesta a la inmunoterapiaПодробнее

SignaCase: A Case Review: How being informed using Signatera helped Dan through his cancer journeyПодробнее

Natera Signatera Product Theater at SABCS 2022: The Cycle of ctDNAПодробнее

John Marshall, MD | What is Signatera?Подробнее

Signatera - ASCO HIGHLIGHTSПодробнее

Arturo Loaiza-Bonilla, MD | What is Signatera?Подробнее

Is the cancer coming back? Using Signatera to detect molecular residual disease (MRD)Подробнее